Refractory urgency incontinence in an older woman with cognitive impairment
A 79-year-old woman lives alone and reports urinary urgency with three incontinence episodes daily, using three pads per day. She has failed pelvic floor muscle training and oxybutynin, which caused confusion and dry mouth. Her Mini-Mental State Examination score is 26, and she takes donepezil. She also has hypertension (148/82 mmHg), chronic constipation, and two falls in the past year. eGFR is 55 mL/min/1.73 m². Postvoid residual is 150 mL. She wants to stop wearing pads and is frightened of becoming more forgetful. She has no recurrent urinary tract infections and no history of radiation or pelvic surgery.
1. What is the next medication change, and what safety issues determine the choice?
Read the worked answer
Stop oxybutynin and avoid further antimuscarinics if possible. Anticholinergic burden is a particular concern with her cognitive impairment, falls, and constipation; oxybutynin is especially likely to cross the blood-brain barrier. A beta-3 agonist is the preferred next step: mirabegron 25 mg daily or vibegron. At an eGFR of 55 mL/min/1.73 m², mirabegron needs no renal dose adjustment (the 25 mg dose is used for severe renal impairment), but blood pressure must be checked and monitored because it can raise blood pressure. Her 148/82 mmHg is not severe uncontrolled hypertension, so a trial is reasonable with follow-up.
Reinforce behavioral measures: timed and urge-suppression voiding, caffeine reduction, and treating constipation. Avoid desmopressin for nocturia in an older woman because of hyponatremia risk. Review donepezil and other medications for urinary effects.
2. How do the postvoid residual and constipation affect the plan, and when would you move to third-line therapy?
Read the worked answer
A postvoid residual of 150 mL is borderline and should be rechecked; it does not by itself contraindicate a beta-3 agonist, but it raises concern about incomplete emptying if it rises above roughly 200–300 mL or if she develops recurrent urinary tract infections. Constipation worsens urgency and incomplete emptying, so an aggressive bowel regimen is part of treating the bladder.
If symptoms remain bothersome after an adequate beta-3 agonist trial and behavioral therapy, third-line options are percutaneous tibial nerve stimulation, sacral neuromodulation, and intradetrusor onabotulinumtoxinA 100 units. Botulinum toxin carries a higher retention risk with a baseline residual of 150 mL, so she must be willing and able to perform clean intermittent catheterization. Sacral neuromodulation requires the ability to use the device and attend programming visits, which may be difficult with cognitive impairment.
3. If she develops recurrent urinary tract infections and the residual rises to 300 mL, what sequence do you recommend?
Read the worked answer
First distinguish incomplete emptying from infection-related urgency. Recheck the residual by catheterization or bladder scan, treat the infection with culture-directed antibiotics, and optimize constipation and mobility. If the residual is consistently 300 mL with recurrent infections, incomplete emptying is contributing, and I would teach clean intermittent catheterization rather than place an indwelling catheter. An indwelling catheter increases bacteriuria, stones, and erosion risk.
If she cannot perform catheterization and has recurrent febrile infections, a suprapubic catheter may be preferable to a long-term urethral catheter. Botulinum toxin should be used cautiously, if at all, in this setting because it can worsen retention. For refractory urgency without retention, PTNS or sacral neuromodulation remain options, but her cognitive status and fall risk make adherence and device use important limiting factors.